SV1998000050A - Metodos mejorados para procesar proteina c actividad - Google Patents

Metodos mejorados para procesar proteina c actividad

Info

Publication number
SV1998000050A
SV1998000050A SV1998000050A SV1998000050A SV1998000050A SV 1998000050 A SV1998000050 A SV 1998000050A SV 1998000050 A SV1998000050 A SV 1998000050A SV 1998000050 A SV1998000050 A SV 1998000050A SV 1998000050 A SV1998000050 A SV 1998000050A
Authority
SV
El Salvador
Prior art keywords
activity
improved methods
processing protein
protein
present
Prior art date
Application number
SV1998000050A
Other languages
English (en)
Spanish (es)
Inventor
Andrew David Carlson
Theodore Balberyszski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV1998000050A publication Critical patent/SV1998000050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SV1998000050A 1997-04-28 1998-04-27 Metodos mejorados para procesar proteina c actividad SV1998000050A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
SV1998000050A true SV1998000050A (es) 1999-01-13

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
SV1998000051A SV1998000051A (es) 1997-04-28 1998-04-27 Formulaciones de proteina c activada. ref. x-11408
SV1998000050A SV1998000050A (es) 1997-04-28 1998-04-27 Metodos mejorados para procesar proteina c actividad

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SV1998000051A SV1998000051A (es) 1997-04-28 1998-04-27 Formulaciones de proteina c activada. ref. x-11408

Country Status (34)

Country Link
US (4) US6159468A (en:Method)
EP (2) EP0875252B1 (en:Method)
JP (2) JP4383547B2 (en:Method)
KR (2) KR100564189B1 (en:Method)
CN (2) CN1235638C (en:Method)
AR (2) AR015598A1 (en:Method)
AT (1) ATE285788T1 (en:Method)
AU (2) AU740753C (en:Method)
BR (2) BR9809292A (en:Method)
CA (2) CA2287267C (en:Method)
CO (2) CO4950523A1 (en:Method)
CZ (1) CZ298429B6 (en:Method)
DE (1) DE69828330T2 (en:Method)
DK (1) DK0875252T3 (en:Method)
EA (2) EA002149B1 (en:Method)
EG (1) EG23685A (en:Method)
ES (1) ES2234072T3 (en:Method)
HU (2) HUP0003401A3 (en:Method)
ID (2) ID22933A (en:Method)
IL (2) IL132325A (en:Method)
IN (2) IN183798B (en:Method)
MY (2) MY120984A (en:Method)
NO (2) NO995134L (en:Method)
NZ (2) NZ337828A (en:Method)
PE (2) PE86299A1 (en:Method)
PL (2) PL195090B1 (en:Method)
PT (1) PT875252E (en:Method)
SI (1) SI0875252T1 (en:Method)
SV (2) SV1998000051A (en:Method)
TR (2) TR199902631T2 (en:Method)
TW (2) TWI242443B (en:Method)
UA (2) UA55448C2 (en:Method)
WO (2) WO1998048818A1 (en:Method)
ZA (2) ZA983496B (en:Method)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287267C (en) * 1997-04-28 2006-08-15 Eli Lilly And Company Improved methods for processing activated protein c
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1128842B1 (en) * 1998-11-13 2006-03-15 Eli Lilly And Company Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
DE69906568T2 (de) * 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
BR9915984A (pt) * 1998-12-10 2001-09-04 Lilly Co Eli Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) * 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
US7430476B2 (en) 2001-02-19 2008-09-30 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7674769B2 (en) 2001-10-15 2010-03-09 Novartis Vaccines And Diagnostics, Inc. Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
PL370652A1 (en) 2001-12-21 2005-05-30 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
CN1708314A (zh) * 2002-10-29 2005-12-14 阿尔萨公司 稳定化的固态多肽微粒
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3189831A1 (en) * 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9357765B2 (en) 2012-04-03 2016-06-07 Smiths Medical Asd, Inc. Heparain-bulking agent compositions and methods thereof
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
IN2014DN11181A (en:Method) 2012-07-04 2015-10-02 Univ Sydney
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
DK3131572T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc-analog til anvendelse til sårheling
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
NZ788906A (en) * 2016-06-01 2025-07-25 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CA2287267C (en) * 1997-04-28 2006-08-15 Eli Lilly And Company Improved methods for processing activated protein c
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
TWI242443B (en) 2005-11-01
AU740753B2 (en) 2001-11-15
CA2288143C (en) 2012-08-21
AR012010A1 (es) 2000-09-13
CZ381099A3 (cs) 2000-03-15
AR015598A1 (es) 2001-05-16
NZ500346A (en) 2001-08-31
PL195642B1 (pl) 2007-10-31
EG23685A (en) 2007-05-09
PL336420A1 (en) 2000-06-19
TR199902631T2 (xx) 2000-01-21
KR100450856B1 (ko) 2004-10-02
ID22933A (id) 1999-12-16
NO995198D0 (no) 1999-10-25
BR9809304B1 (pt) 2011-02-08
NZ337828A (en) 2001-06-29
TW585871B (en) 2004-05-01
MY118591A (en) 2004-12-31
PE84799A1 (es) 1999-09-16
US6159468A (en) 2000-12-12
EA002149B1 (ru) 2001-12-24
HU224826B1 (en) 2006-02-28
HUP0003401A2 (hu) 2001-02-28
JP4383546B2 (ja) 2009-12-16
KR20010020325A (ko) 2001-03-15
CO4940438A1 (es) 2000-07-24
CN1235638C (zh) 2006-01-11
CO4950523A1 (es) 2000-09-01
NO995134D0 (no) 1999-10-21
CZ298429B6 (cs) 2007-10-03
HUP0100284A3 (en) 2003-08-28
KR100564189B1 (ko) 2006-03-27
HUP0100284A2 (hu) 2001-06-28
US6395270B1 (en) 2002-05-28
PL336889A1 (en) 2000-07-17
IN183798B (en:Method) 2000-04-15
EA199900980A1 (ru) 2000-04-24
SI0875252T1 (en) 2005-06-30
EP0875252A3 (en) 2000-07-26
DE69828330T2 (de) 2005-10-13
US6162629A (en) 2000-12-19
CA2288143A1 (en) 1998-11-05
EP0875252A2 (en) 1998-11-04
IL132325A (en) 2005-07-25
DK0875252T3 (da) 2005-04-25
CA2287267A1 (en) 1998-11-05
CN1261280A (zh) 2000-07-26
ID23172A (id) 2000-03-23
CN1227025C (zh) 2005-11-16
HK1016472A1 (en) 1999-11-05
BR9809304A (pt) 2000-10-17
EA004881B1 (ru) 2004-08-26
EP0875563A3 (en) 2000-08-02
NO995134L (no) 1999-12-21
ATE285788T1 (de) 2005-01-15
PT875252E (pt) 2005-03-31
EP0875252B1 (en) 2004-12-29
AU740753C (en) 2002-10-10
WO1998048822A1 (en) 1998-11-05
BR9809292A (pt) 2000-07-04
KR20010020242A (ko) 2001-03-15
ES2234072T3 (es) 2005-06-16
JP2001527543A (ja) 2001-12-25
CA2287267C (en) 2006-08-15
AU7258998A (en) 1998-11-24
IL132502A0 (en) 2001-03-19
HUP0003401A3 (en) 2003-01-28
NO995198L (no) 1999-10-25
MY120984A (en) 2005-12-30
CN1254284A (zh) 2000-05-24
EP0875563A2 (en) 1998-11-04
TR199902529T2 (xx) 2000-02-21
ZA983497B (en) 1999-10-25
SV1998000051A (es) 1998-12-11
US6436397B1 (en) 2002-08-20
WO1998048818A1 (en) 1998-11-05
UA73071C2 (en) 2005-06-15
AU743531B2 (en) 2002-01-31
JP2001524111A (ja) 2001-11-27
ZA983496B (en) 1999-10-25
UA55448C2 (uk) 2003-04-15
PE86299A1 (es) 1999-09-17
AU7161898A (en) 1998-11-24
IL132325A0 (en) 2001-03-19
DE69828330D1 (de) 2005-02-03
JP4383547B2 (ja) 2009-12-16
IN187157B (en:Method) 2002-02-16
PL195090B1 (pl) 2007-08-31
EA199900979A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
SV1998000050A (es) Metodos mejorados para procesar proteina c actividad
DE69806498D1 (de) Behandlung von kontaktlinsen mit wässrigen, alkalicarbonat-haltigen lösungen
FI950459L (fi) Argatrobaanin konsentroituja vesiliuoksia
BR9407264A (pt) Composição aquosa e método para tratar lentes de contato
DE69626976D1 (de) BEHANDLUNG EINER PROTEINLÖSUNG MIT A1/Fe UND ANSCHLIESENDE MEMBRANKONZENTRATION
DE69711034D1 (de) Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
DE69614516D1 (de) Nanofiltration von konzentrierten wässrigen salzlösungen
FI955205A7 (fi) Menetelmä tertiaaristen amiinioksidien vesiliuosten puhdistamiseksi
RS51512B (sr) Postupak za prečišćavanje interferonskih proteina pomoću katjonske izmenjivačke hromatografije
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
NO971723L (no) Fremgangsmåte ved rensning av vandige, tertiære aminoksydopplösninger
BR9005763A (pt) Utilizacao de aminoacidos protegidos contra o ph do rumen na alimentacao do carneiro
DE69500167D1 (de) Wässrige Lösung zur Oberflächenbehandlung von Metallen
PT1003710E (pt) Processo de tratamento de solucoes aquosas que compreendem acidos e compostos nitrados
PT840746E (pt) Metodo para purificacao de proteinas
UA39178C2 (uk) Спосіб мінімізації деградації активованого протеїну с (варіанти), фармацевтична композиція та водний розчин активованого протеїну с
FI953018L (fi) Menetelmä vesipitoisten liuosten tai dispersioiden säilyttämiseksi
ATE309371T1 (de) Protein mit dnase-aktivität
PT854862E (pt) Processo para a preparacao de um aminoacido activado
RU95110637A (ru) Аффинный сорбент для удаления фактора некроза опухоли и способ его получения
BR9804846A (pt) M-todo de tratamento e quadro de bicicleta contra corrosÆo e quadro de bicicleta assim obtido
DE69712190D1 (de) Behandlung von kontaktlinsen mit wässriger lösung von phophonsäurederivaten
ECSP982488A (es) Metodos mejorados para procesamiento de proteina c activada
MD654F1 (ro) Procedeu de prelucrare a tutunului Process of tobacco treatment
DE69711609D1 (de) Verfahren zum entfernen von unkonventionellen krankheitserregern aus proteinlösungen

Legal Events

Date Code Title Description
FD Lapse